Nanovibronix, INC

ENvue Medical announces board changes with two resignations and the appointment of two new directors, including a new Board Chairman.

ENvue Medical has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, potentially leading to delisting.

ENvue Medical, Inc. announced an amendment to CEO Doron Besser's employment agreement and the appointment of David Johnson as Chairman of the Board, detailing their compensation and equity grants.

ENvue Medical, Inc. amended its Series H Convertible Preferred Stock terms, removing the floor price in exchange for a $2.5 million additional investment from holders.

ENvue Medical, Inc. has amended its 2024 Long-Term Incentive Plan to incorporate Israeli tax law compliance and reflect recent corporate updates.

ENvue Medical, Inc. announced an amended employment agreement for CEO Doron Besser, M.D., increasing his salary and equity, and appointed Nicole Fernandez-McGovern as Interim CFO following Stephen Brown's departure.

ENvue Medical, Inc. reported a significant revenue decrease for the first quarter of 2026, primarily due to the market removal of a key product, while also highlighting ongoing liquidity concerns.

NanoVibronix reports increased Q3 2025 revenue driven by the ENvue merger, despite continued operating losses, a going concern warning, and product withdrawal.

NanoVibronix, Inc. reported a significant increase in net loss and declining revenues for Q2 2025, alongside a recent merger, multiple reverse stock splits, and a product withdrawal.

NanoVibronix's Q1 2025 results reflect the impact of the ENvue merger and a reverse stock split, with increased revenue offset by higher operating expenses and a net loss.

NanoVibronix saw a significant increase in revenue year-over-year but continues to experience net losses and faces substantial doubt about its ability to continue as a going concern.

NanoVibronix saw a significant increase in revenue during the second quarter of 2024, but the company's financial statements raise substantial doubt about its ability to continue as a going concern.

ENvue Medical, Inc. (formerly NanoVibronix, Inc.) filed its annual report detailing significant operational changes, including a merger and reverse stock splits, while addressing Nasdaq listing requirements and ongoing financial challenges.

NanoVibronix finalizes its merger with ENvue Medical, secures $1.3 million in debenture financing, and implements a 1-for-11 reverse stock split to meet Nasdaq requirements.

NanoVibronix files an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

NanoVibronix has filed an amendment to its annual report to correct the location of its former auditor's consent and include updated certifications.

NanoVibronix, Inc. details its capital structure, product development, and regulatory strategies in its annual 10-K filing.

Christian Michael Glibert is no longer a 10% beneficial owner of ENvue Medical, Inc. due to share dilution from a merger.

ENvue Medical, Inc. Director and 10% owner Christian Michael Glibert acquired 240,000 shares of common stock.

Bank of America and its subsidiaries reported significant sales of ENvue Medical, Inc. common stock, reducing their indirect beneficial ownership to 8 shares.

NanoVibronix CEO, Brian M. Murphy, acquired 80,000 stock options at an exercise price of $0.5995 on December 30, 2024.

Director Thomas Mika acquired 20,000 options to purchase common stock of NanoVibronix, Inc. on December 30, 2024.

NanoVibronix's Chief Financial Officer, Stephen Russell Brown, acquired 50,000 options to purchase common stock at $0.5995 per share on December 30, 2024.

ENvue Medical, Inc. is holding a special meeting of stockholders on August 14, 2026, to vote on a proposal to effect a reverse stock split of its common stock, ranging from 1-for-2 to 1-for-50, to regain compliance with Nasdaq's minimum bid price requirement.

NanoVibronix calls 2025 Annual Meeting for votes on board, auditor, incentive plan, and private placement share issuance.

NanoVibronix, Inc. filed a supplement to its definitive proxy statement to correct an inadvertent error regarding the number of outstanding Series G and Series X Preferred Stock shares ahead of its Special Meeting on July 11, 2025.

NanoVibronix, Inc. is calling a Special Meeting of Stockholders on July 11, 2025, to vote on a proposed reverse stock split, ranging from 1-for-2 to 1-for-50, aimed at increasing its per share price to maintain Nasdaq listing compliance.

NanoVibronix is holding a special meeting to seek stockholder approval for a reverse stock split and the issuance of shares related to a warrant exchange, aiming to maintain its Nasdaq listing.

NanoVibronix, Inc. has filed a definitive proxy statement with the SEC.

NanoVibronix launches a firm commitment public offering of Series G Convertible Preferred Stock and warrants to raise approximately $8.2 million for debt redemption and general corporate purposes.

NanoVibronix, Inc. aims to raise capital through a public offering of Series G Convertible Preferred Stock and warrants, with proceeds intended for debt redemption and general corporate purposes.

NanoVibronix, Inc. plans to offer Series G Convertible Preferred Stock and warrants to purchase common stock, aiming to raise up to $10 million.

NanoVibronix aims to secure up to $16 million via an offering of Series G Convertible Preferred Stock and accompanying warrants, with proceeds earmarked for Series X Preferred Stock redemption and general corporate needs.

NanoVibronix, Inc. announces a proposed public offering of Series G Convertible Preferred Stock and warrants to bolster its development programs and strategic acquisitions.

Christian Glibert reports a reduction in beneficial ownership of ENvue Medical to 6.5% due to share issuance.

Christian Glibert has acquired a 22% beneficial ownership stake in ENvue Medical, Inc. for investment purposes.

Bank of America Corporation has filed an amendment to Schedule 13G, disclosing beneficial ownership of 14 shares, representing 0.0% of ENvue Medical, Inc.'s common stock.

Bank of America Corporation has disclosed a 21.5% beneficial ownership stake in ENvue Medical, Inc., holding 234,235 common shares, with a significant warning of potential future dilution.

Alpha Capital Anstalt has reported a 9.99% beneficial ownership stake in NanoVibronix Inc., holding 82,471 shares of common stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in NanoVibronix, Inc.'s common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a shared beneficial ownership of 349,284 common shares, representing 9.99% of NanoVibronix, Inc.